Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | MET | P08581 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.40 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.40 |
| ▸ | DYRK3 | O43781 | 1/20 | 0.39 |
| ▸ | CLK1 | P49759 | 1/20 | 0.39 |
| ▸ | CLK2 | P49760 | 1/20 | 0.39 |
| ▸ | CLK3 | P49761 | 1/20 | 0.39 |
| ▸ | GSK3B | P49841 | 1/20 | 0.39 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.39 |
| ▸ | DYRK2 | Q92630 | 1/20 | 0.39 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.39 |
| ▸ | DYRK4 | Q9NR20 | 1/20 | 0.39 |
| ▸ | DYRK1B | Q9Y463 | 1/20 | 0.39 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.39 |
| ▸ | MMP13 | P45452 | 2/20 | 0.38 |
| ▸ | MAPT | P10636 | 3/20 | 0.38 |
| ▸ | TP53 | P04637 | 2/20 | 0.38 |
| ▸ | CTSL | P07711 | 2/20 | 0.38 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16976838 | 0.88 | GRIN1 (0.46) | GAAMETKDM4ECYP11B2ADORA3 | |
| SCHEMBL14554321 | 0.83 | CTSL (0.48) | METKDM4ECTSLMEN1KMT2A | |
| SCHEMBL1573111 | 0.79 | PDE5A (0.51) | GAAMETKDM4ECYP11B2ADORA3 | |
| SCHEMBL9905400 | 0.76 | GAA (0.47) | GAAKDM4EADORA3MMP13MAPT | |
| SCHEMBL9928536 | 0.76 | GAA (0.39) | GAAMETKDM4ECYP11B2ADORA3 | |
| SCHEMBL16298436 | 0.75 | GAA (0.50) | GAAKDM4EADORA3ALDH1A1ADORA1 | |
| SCHEMBL20187546 | 0.74 | TRPA1 (0.54) | GAAMETKDM4ECYP11B2GSK3B | |
| SCHEMBL7437138 | 0.73 | SMN1; SMN2 (0.51) | GAAALDH1A1MEN1POLBKMT2A | |
| SCHEMBL9905498 | 0.73 | HPGD (0.47) | GAAMETKDM4ECYP11B2MAPT | |
| SCHEMBL12808668 | 0.72 | NPSR1 (0.49) | GAAMETKDM4ECYP11B2MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2648517-B1 | TRICYCLIC HETEROCYCLES USEFUL AS DIPEPTIDYL PEPTIDASE-IV INHIBITORS | MERCK SHARP & DOHME (US) | 2015-08-05 | — | — | EP | disclosed |
| EP-2648517-B1 | TRICYCLIC HETEROCYCLES USEFUL AS DIPEPTIDYL PEPTIDASE-IV INHIBITORS | MERCK SHARP & DOHME (US) | 2015-08-05 | — | — | EP | disclosed |
| EP-2648517-A1 | TRICYCLIC HETEROCYCLES USEFUL AS DIPEPTIDYL PEPTIDASE-IV INHIBITORS | Merck Sharp & Dohme Corp. (US) | 2013-10-16 | — | — | EP | disclosed |
| US-20130261140-A1 | TRICYCLIC HETEROCYCLES USEFUL AS DIPEPTIDYL PEPTIDASE-IV INHIBITORS | MERCK SHARP & DOHME CORP. | 2013-10-03 | — | — | US | disclosed |
| WO-2012078448-A1 | TRICYCLIC HETEROCYCLES USEFUL AS DIPEPTIDYL PEPTIDASE-IV INHIBITORS | SCHERING CORPORATION (US) | 2012-06-14 | — | — | WO | disclosed |
| WO-2012078448-A1 | TRICYCLIC HETEROCYCLES USEFUL AS DIPEPTIDYL PEPTIDASE-IV INHIBITORS | SCHERING CORPORATION (US) | 2012-06-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130261140-A1 | TRICYCLIC HETEROCYCLES USEFUL AS DIPEPTIDYL PEPTIDASE-IV INHIBITORS | DPP4, DPP7, DPP3 | GAA 87/4885MET 2406/4885KDM4E 1965/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.